Myriad Genetics, Inc. (NASDAQ:MYGN)

CAPS Rating: 5 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

Recs

0
Player Avatar cavrad (< 20) Submitted: 2/23/2011 7:38:37 AM : Outperform Start Price: $18.40 MYGN Score: +38.48

MF

Report this Post Reply

Featured Broker Partners


Advertisement